← 返回

阐明温和磁热疗对 U87 人胶质母细胞瘤细胞的固有免疫效应:一项体外研究

英文原题:Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study.

查看英文原题

Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study.

PubMed 2021/10/12(内容时间) Pharmaceutics Q1 · IF 6.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症免疫疗法已获批作为多种癌症的标准二线治疗,有些情况下甚至可作为一线治疗。然而,免疫治疗在胶质母细胞瘤(GBM)中尚未显示出具有临床意义的成功。这主要是由于大脑的“免疫豁免”状态,以及GBM特有的肿瘤微环境(TME):其中TIL(肿瘤浸润淋巴细胞)缺乏,并形成免疫抑制机制。本文研究一种局部温和热疗方法:立方体氧化铁磁性纳米颗粒(大小约17 nm)暴露于外部交变磁场(AMF)后产生热量,以在U87胶质母细胞瘤细胞中诱导免疫原性细胞死亡(ICD)。与其他肿瘤类型的观察结果一致,我们发现温和磁热疗(MHT)可调节U87胶质母细胞瘤细胞的免疫学特征,诱导应激相关信号,从而增强巨噬细胞对U87细胞的吞噬和杀伤。

同时,我们证明,对U87细胞进行温和磁热疗会调节NK细胞抑制性和激活性配体的表达。有趣的是,MHT处理后U87细胞的NK配体表达变化增强了其对NK细胞杀伤的易感性,并提高了NK细胞功能。总体结果显示,温和MHT可诱导ICD,并通过上调特定应激配体使GBM细胞更易被NK细胞杀伤,为GBM治疗提供一种新的免疫治疗方法;该方法可能与现有NK细胞疗法产生协同作用,从而改善治疗结局。

展开英文摘要原文

Cancer immunotherapies have been approved as standard second-line or in some cases even as first-line treatment for a wide range of cancers.

However, immunotherapy has not shown clinically relevant success in glioblastoma (GBM). This is principally due to the brain's "immune-privileged" status and the peculiar tumor microenvironment (TME) of GBM characterized by a lack of tumor-infiltrating lymphocytes and the establishment of immunosuppressive mechanisms.

Herein, we explore a local mild thermal treatment, generated via cubic-shaped iron oxide magnetic nanoparticles (size ~17 nm) when exposed to an external alternating magnetic field (AMF), to induce immunogenic cell death (ICD) in U87 glioblastoma cells. In accordance with what has been observed with other tumor types, we found that mild magnetic hyperthermia (MHT) modulates the immunological profile of U87 glioblastoma cells by inducing stress-associated signals leading to enhanced phagocytosis and killing of U87 cells by macrophages.

At the same time, we demonstrated that mild magnetic hyperthermia on U87 cells has a modulatory effect on the expression of inhibitory and activating NK cell ligands. Interestingly, this alteration in the expression of NK ligands in U87 cells upon MHT treatment increased their susceptibility to NK cell killing and enhanced NK cell functionality.

The overall findings demonstrate that mild MHT stimulates ICD and sensitizes GBM cells to NK-mediated killing by inducing the upregulation of specific stress ligands, providing a novel immunotherapeutic approach for GBM treatment, with potential to synergize with existing NK cell-based therapies thus improving their therapeutic outcomes.

论文信息

作者
Persano S、Vicini F、Poggi A、Fernandez JLC、Rizzo GMR、Gavilán H、Silvestri N、Pellegrino T
单位
Nanomaterials for Biomedical Applications Department, Istituto Italiano di Tecnologia (IIT), via Morego 30, 16163 Genoa, Italy.Italy
期刊
Pharmaceutics2021 Oct 12
原文标识
PubMed 34683961 · DOI 10.3390/pharmaceutics13101668